Yüklüyor......
Hemolytic anemia after switching from infliximab originator to biosimilar CT‐P13 in a patient with inflammatory bowel disease: A case report
Available data on switching from originator infliximab to CT‐P13 in patients with inflammatory bowel disease are reassuring regarding safety and efficacy outcomes. However, monitoring of such patients, especially in the early phase after switching, is important given the possibility that rare side e...
Kaydedildi:
| Yayımlandı: | Clin Case Rep |
|---|---|
| Asıl Yazarlar: | , , |
| Materyal Türü: | Artigo |
| Dil: | Inglês |
| Baskı/Yayın Bilgisi: |
John Wiley and Sons Inc.
2019
|
| Konular: | |
| Online Erişim: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6878056/ https://ncbi.nlm.nih.gov/pubmed/31788249 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/ccr3.2394 |
| Etiketler: |
Etiketle
Etiket eklenmemiş, İlk siz ekleyin!
|